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NICE ﬁ rst. Nineteen of the 46 submissions were appraised by NICE; 10% of the cases
were ﬁ rst assessed by NICE, 60% were appraised by NICE second, and in 30% of 
the cases, NICE were the last in the sequence to appraise. It is interesting to note that 
the rate of acceptance by the SMC was approximately 65% regardless of whether the
intervention was appraised by the SMC or CADTH ﬁ rst. In contrast the acceptance 
rate for CADTH was observed to be much higher when interventions were appraised 
by the SMC ﬁ rst compared to when CADTH conducted the ﬁ rst appraisal; 56% and 
20% respectively. CONCLUSIONS: The SMC have generally received submissions 
before NICE and CADTH. In comparison, NICE were rarely the ﬁ rst to appraise an
intervention. Reviewing the sequence in which submissions are appraised by each of 
these bodies and the inﬂ uence of this on the guidance issued may inform future stra-
tegic planning of submissions.
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OBJECTIVES: Health technology assessment (HTA) is the process used to evaluate
emerging and existing technologies (e.g., pharmaceuticals, medical devices, and diag-
nostics), and to determine how these technologies will impact health care service
delivery and society. Despite the growing importance of HTA as a decision tool to 
govern the adoption process for emerging technologies, a systematic and hierarchical 
approach to characterize the decision-making process used by various countries has 
not been developed. The objective of this study was to model the decision pathway
that describes the underlying decision-making structure and process for HTA in eight 
selected countries. METHODS: Members of the International Society for Pharmaco-
economics and Outcomes Research Special Interest Group for HTA performed 
research online to identify resources that described health systems and decision path-
ways for the following countries: Australia, Canada, France, Germany, Spain, Sweden, 
UK, and the United States. Once proposed decision structures were reviewed by com-
mittee members familiar with that country, decision models were developed for each 
country and validated for clarity and accuracy. RESULTS: The HTA decision-making 
hierarchy developed for each country identiﬁ ed the decision maker as the payer (i.e., 
person or organization) who makes the ﬁ nal decision for coverage and payment for 
an approved technology. The evaluator was deﬁ ned as a person or organization that 
provides input into the decision-making process via HTA development, but did not 
make the ﬁ nal decision for coverage and payment. The decision-making process
referred to the HTA evaluation process, as deﬁ ned in the public domain, for emerging 
technologies in consideration for coverage and payment. CONCLUSIONS: Each of 
the countries examined utilized a unique decision-making structure and maintained
detailed processes for HTA input to the ﬁ nal decision maker. Decision pathways for
HTA in the countries examined continue to evolve in response to societal needs for 
emerging technologies.
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OBJECTIVES: Health technology assessment (HTA) started in the United States (US)
to quantify the beneﬁ ts, harms and costs associated with new technologies. Paralleling 
methodological advances, applied HTA processes were instituted in many countries
to inform decisions about adopting new technologies. Within the context of discus-
sions regarding a new center for comparative effectiveness in the US, we compared
HTA of medications in six jurisdictions: Australia, Canada, England and Wales, the
Netherlands, Scotland and Sweden. The objective was to identify characteristics
of HTA processes and agencies that may inform the structure and operation of a
US center for comparative effectiveness. METHODS: We identiﬁ ed characteristics
of each health care system and HTA processes, including: the medications reimburse-
ment processes; whether recommendations are mandatory; and structure and transpar-
ency of the process using the accountability for reasonableness framework. RESULTS:
For Australia, England and Wales and the Netherlands, reimbursement decisions
are made nationally, while in Canada, Scotland, and Sweden, formularies are main-
tained regionally. HTA processes range from manufacturer-prepared single product 
submissions to comprehensive assessments based on de novo analyses. While six 
jurisdictions have quasi-governmental HTA agencies, the Netherlands relies largely on 
a reference-pricing system. Sweden has two HTA agencies: one for rapid assessment
of single medications and another which undertakes multiple-technology assessments 
involving other funding silos. Scotland, and to lesser extents England and Wales 
and Sweden, have implemented transparent processes, e.g., by posting meeting
minutes and the reasoning for recommendations. CONCLUSIONS: The US health 
care system is fragmented and characterized by insured populations with different
health needs. Characteristics directly relevant to a US centre include having: non-
mandatory recommendations; and transparent two-tiered processes. Collecting better
evidence on real-world treatment effects – as is being done in some jurisdictions – 
would increase the number and types of stakeholders who could apply the information 
for decision-making.
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OBJECTIVES: To assess the impact electronic prescribing system the use of an has on 
a provider’s prescribing of low cost generic drugs through lower costing channels. 
METHODS: Generic/brand, mail/retail, and cost-per-day (costs) for over nine million
adjudicated prescriptions dispensed between July 2002 and December 2005 were 
incorporated into independent multivariate logistic and general linear models to 
compare prescriptions from 468 providers prescribed before and after using an elec-
tronic prescribing system and 28,734 “no use” (control) providers. Separate models 
for ACE Inhibitors, ARB and ARB Combinations, H2 Antagonists, HMG Inhibitors, 
NSAIDs, PPIs, and SSRIs classes included independent variables for: provider degree, 
specialty, and electronic prescribing system use (no, little and regular use prescribed
50 prescriptions/month); patient sex, age (continuous), and regimen status; claim 
month and distribution channel (except in mail/retail models). Signiﬁ cance was a 
p-value a0.01. RESULTS: Generic and mail prescriptions were generally more likely 
to be prescribed from providers with regular use (ORs: 0.80pC1.20) and less likely
from those with little or no use (ORs: 0.65pC1.23) than prescriptions from the pre-
period of providers who became regular users (OR  1.00), with most signiﬁ cant and 
few exceptions. Costs were generally lower for providers with regular use (CEs: 
$0.33pC$0.04) and higher for providers with little or no use (CEs: $0.13pC$0.14) 
than prescriptions from the pre-period of providers who became regular users (CE 
$0.00), with some signiﬁ cant and some exceptions. CONCLUSIONS: Similar underly-
ing patterns found across multiple classes provide support for linking regular use of 
electronic prescribing systems to providers being even more likely to prescribe generics 
drugs and having them dispensed through mail, both of which likely lower overall 
costs. Additional research should be performed to better assess the robustness of these 
ﬁ nding as participation expands and in more therapeutic classes.
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OBJECTIVES: To determine whether the implementation of Medicare Part D coverage 
affected trends in average per physician prescription volume of select drugs in the six
classes deemed by CMS/Medicare Part D to be medically necessary for reimbursement.
To assess these trends over the 2005–2008 period, including the January 1, 2006 
implementation of Medicare Part D. To investigate whether prescribers of different 
specialties were affected to a greater of lesser extent than their peers. METHODS: For 
each of the six protected classes deﬁ ned by CMS (Antineoplastics, Antidepressants, 
Anticonvulsants, Immunosuppressants, Antipsychotics, Antiretrovirals) a comparative 
market basket consisting of the top 2 prescribed anticonvulsants (clonazepam, gaba-
pentin), antidepressants (escitaprolam, ﬂ uoxetine), antipsychotics (quetiapine, risperi-
done), HIV/AIDS (emtricitabine/tenofovir, ritonavir) and immunosuppressants 
(azathioprine, mycophenolate) were selected based on total prescriptions (TRx) 
between January 2005 and June 2008. For that time frame, average prescription 
volume, by individual physician, were collected monthly using SDI/ Verispan’s VONA 
and VOPA databases. RESULTS: Of 103 physician specialty/molecule prescribing 
pairs, average monthly prescription volume for the 12 month period after implementa-
tion of Medicare Part D (January 2006 – December 2006) coverage increased signiﬁ -
cantly (p  0.05) versus the prior 12 months (January 2005-December 2005 for 79% 
(34/43) of combinations examined, and conversely, a signiﬁ cant (p  0.05) decrease 
was observed for 80% (48/60) combinations. CONCLUSIONS: The introduction of 
Medicare Part D had signiﬁ cant impact on utilization for the majority of high volume 
drugs in the Medicare Part D designated protected classes. A possible explanation is
that the reorganization of formulary structures and tier placement for many of these 
drugs led to pricing changes for patients, which in turn were observed by physicians 
and led to subtle but signiﬁ cant changes in prescribing behavior. In addition to changes
for specialty physicians, signiﬁ cant changes in volume were also noted for GP/FP/IM
physicians. Ongoing investigation into drug pricing and tier placement may lead to 
greater clarity.
